This regulatory update summarizes a study comparing Frexalimab to Tacrolimus in adults undergoing kidney transplantation and notes sponsor details and current enrollment status.
The trial targets adults receiving kidney transplants and lists Frexalimab and Tacrolimus as the primary comparative agents. The immunosuppression regimens referenced include rabbit anti thymocyte globulin, mycophenolate mofetil or mycophenolate sodium, and steroids such as methylprednisolone or prednisone. The sponsor is Sanofi and the study status is not yet recruiting, with ClinicalTrials.gov registration under NCT07412470.
The document frames the investigation within a standard immunosuppressive context and signals an intent to assess safety signals and potential performance within such regimens, rather than report results at this stage.
In this article you will find a compact navigation block to help readers jump to key topics after the introduction.
In this article
- Study design and interventions
- Safety and efficacy considerations
- Regulatory context and sponsor information
- Frequently asked questions
- Implications for readers
What is the study design and who is involved?
The registry describes a trial enrolling adults undergoing kidney transplantation with a head to head comparison between Frexalimab and Tacrolimus as the central acute treatment decision. The immunosuppressive framework appears to include induction and maintenance components such as rabbit anti thymocyte globulin and maintenance agents like mycophenolate mofetil or mycophenolate sodium along with steroids including methylprednisolone or prednisone. The sponsor is Sanofi and the entry notes that recruitment has not yet begun, with the ClinicalTrials.gov identifier NCT07412470 serving as the public reference.
Who is eligible and how is the comparison set up?
The description points to adults undergoing transplantation as the eligible population and positions Frexalimab as the investigational agent in direct comparison with Tacrolimus. The surrounding regimen implies compatibility with common induction and maintenance therapies used in complex immunosuppression plans to support graft outcomes.
What safety and efficacy signals are described?
The record highlights an emphasis on safety signals associated with the immunosuppressive strategy and potential efficacy signals related to rejection risk and graft survival. No trial results are provided in the source text, and the aim is to gather data within a predefined regimen rather than publish outcomes at this stage.
What regulatory considerations matter?
Key items for regulators include the sponsor name Sanofi and the trial identifier NCT07412470, which support transparency and traceability. The inclusion of Frexalimab and Tacrolimus within a wider immunosuppressive plan aligns with a regulatory minded review of safety in complex regimens for kidney transplantation.
What is the regulatory and sponsor context?
The study is listed by a sponsor and is not yet recruiting. The ClinicalTrials.gov record provides a public reference for investigators, patients, and regulators. The sponsor is Sanofi and the listing confirms plans to compare Frexalimab with Tacrolimus in the described patient population. The provided link serves as the official registry entry for this trial.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07412470?term=medical+device
Frequently asked questions
- 1. What is the focus of the trial
The trial is a direct comparison between Frexalimab and Tacrolimus in adult kidney transplant recipients as part of a broader immunosuppression plan.
- 2. Who funds the trial
Sanofi is listed as sponsor in the registry excerpt.
- 3. What is the recruitment status
Not yet recruiting.
- 4. Where can I find the registry entry
The ClinicalTrials.gov entry is NCT07412470 and the registry link appears in this article as the official reference.
Conclusion and implications
Readers such as clinicians regulators and industry observers should track the registry for updates on enrollment and any safety reports. The direct comparison of Frexalimab to Tacrolimus in this kidney transplant setting aims to add to the evidence base guiding immunosuppression strategies. Regulatory disclosure and ongoing safety monitoring will shape future discussions on labeling and clinical use within post transplant care.
Disclaimer for professionals
This article is intended for professionals and is not legal advice or regulatory guidance. It reflects information from the source text and does not constitute endorsement or specific regulatory interpretation.